Ignite Creation Date:
2024-05-06 @ 5:32 PM
Last Modification Date:
2024-10-26 @ 2:31 PM
Study NCT ID:
NCT05347511
Status:
UNKNOWN
Last Update Posted:
2022-04-26
First Post:
2022-04-20
Brief Title:
Study of the Pronostic Impact of Immunohistochemical Histological and Radiological Factors in Patients With Primary Central Nervous System Lymphoma
Sponsor:
Central Hospital Nancy France
Organization:
Central Hospital Nancy France
Study Overview
Official Title:
Study of the Pronostic Impact of Immunohistochemical Histological Radiological and Molecular Factors in Patients With Primary Central Nervous System Lymphoma
Status:
UNKNOWN
Status Verified Date:
2022-04
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primary Central Nervous System Lymphoma PCNSL have a specific mutational profile in comparison to systemic diffuse large cells lymphoma DLBCLs that can be related to the expression of immunohistochemical markers as cyclon NPM1 CD30 and P53 which could be predictive factor for prognosis andor chemotherapy response The main objective of this study is to identify new prognostic factors and new potential therapeutic targets
The secondary objectives are to correlate the histological the radiological and the clinicals informations of these patients
The secondary objectives are to correlate the histological the radiological and the clinicals informations of these patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None